TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07705334: A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

Sponsor: SHY Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT07705334 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07705334 Rescue Dossier →